fluvoxamine

Also known as Luvox®, U-23000, Fluvoxaminum, Fluvoxamina

Fluvoxamine, sold under the brand name Luvox among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is primarily used to treat major depressive disorder and, perhaps more-especially, obsessive–compulsive disorder (OCD), but is also used to treat anxiety disorders such as panic disorder, social anxiety disorder, and post-traumatic stress disorder.

Key facts

Drug.Verifiedfields: changed
Drug.Watchedfields: changed
Drug.verifiedrevid: 443824781
Drug.image: Fluvoxamine.svg
Drug.image_class: skin-invert-image
Drug.image2: FLUVOXAMINE_3d-ball-and-stick.png
Drug.image_class2: bg-transparent
Drug.width2: 276
Drug.pronounce: UK: US:
Drug.tradename: Luvox, others
Drug.MedlinePlus: a695004
Drug.DailyMedID: Fluvoxamine
Drug.pregnancy_AU

~17 min read

Article

14 sections

Contents

Medical uses
Adverse effects
Common
Uncommon
Rare
Unknown frequency
Interactions
Pharmacology
Pharmacodynamics
Pharmacokinetics
History
Research directions
Environment
References

{{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 443824781 | image = Fluvoxamine.svg | image_class = skin-invert-image | width = | alt = | caption = | image2 = FLUVOXAMINE_3d-ball-and-stick.png | image_class2 = bg-transparent | width2 = 276 | alt2 = | pronounce = UK: US: | tradename = Luvox, others | Drugs.com = | MedlinePlus = a695004 | DailyMedID = Fluvoxamine | pregnancy_AU = C | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = Selective serotonin reuptake inhibitor (SSRI) | ATC_prefix = N06 | ATC_suffix = AB08 | ATC_supplemental = | legal_AU = S4 | legal_AU_comment = | legal_BR = C1 | legal_BR_comment = | legal_CA = Rx-only | legal_CA_comment = | legal_DE = | legal_DE_comment = | legal_NZ = | legal_NZ_comment = | legal_UK = POM | legal_UK_comment = | legal_US = Rx-only | legal_US_comment = | legal_UN = | legal_UN_comment = | legal_status =

| bioavailability = 53% (90% confidence interval: 44–62%) | protein_bound = 77–80% | metabolism = Liver (primarily O-demethylation)Major: CYP2D6 or CYP1A2Minor: CYP3A4, CYP2C19, and/or CYP1A2 | metabolites = | onset = | elimination_half-life = 12–13 hours (single dose), 22 hours (repeated dosing) | duration_of_action = | excretion = Kidney (98%; 94% as metabolites, 4% as unchanged drug)